Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free GUTS Stock Alerts

Fractyl Health (GUTS) Competitors

Fractyl Health logo
$0.69 -0.03 (-4.57%)
Closing price 04:00 PM Eastern
Extended Trading
$0.69 0.00 (-0.42%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GUTS vs. DCTH, CLPT, CV, RXST, and TLSI

Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include Delcath Systems (DCTH), ClearPoint Neuro (CLPT), CapsoVision (CV), RxSight (RXST), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.

How does Fractyl Health compare to Delcath Systems?

Fractyl Health (NASDAQ:GUTS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Fractyl Health currently has a consensus price target of $5.40, suggesting a potential upside of 678.21%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 95.14%. Given Fractyl Health's higher possible upside, analysts clearly believe Fractyl Health is more favorable than Delcath Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Delcath Systems
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Fractyl Health has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Delcath Systems has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fractyl HealthN/AN/A-$140.95M-$1.84N/A
Delcath Systems$85.23M4.66$2.70M$0.07164.71

61.1% of Delcath Systems shares are owned by institutional investors. 26.1% of Fractyl Health shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Fractyl Health had 1 more articles in the media than Delcath Systems. MarketBeat recorded 3 mentions for Fractyl Health and 2 mentions for Delcath Systems. Fractyl Health's average media sentiment score of 1.90 beat Delcath Systems' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Delcath Systems
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Delcath Systems has a net margin of 3.17% compared to Fractyl Health's net margin of 0.00%. Delcath Systems' return on equity of 2.63% beat Fractyl Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Fractyl HealthN/A -2,896.77% -104.24%
Delcath Systems 3.17%2.63%2.39%

Summary

Delcath Systems beats Fractyl Health on 10 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to ClearPoint Neuro?

Fractyl Health (NASDAQ:GUTS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

ClearPoint Neuro has higher revenue and earnings than Fractyl Health. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fractyl HealthN/AN/A-$140.95M-$1.84N/A
ClearPoint Neuro$36.97M9.00-$25.54M-$0.91N/A

30.1% of ClearPoint Neuro shares are owned by institutional investors. 26.1% of Fractyl Health shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Fractyl Health currently has a consensus price target of $5.40, suggesting a potential upside of 678.21%. ClearPoint Neuro has a consensus price target of $14.50, suggesting a potential upside of 30.63%. Given Fractyl Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Fractyl Health is more favorable than ClearPoint Neuro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
ClearPoint Neuro
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Fractyl Health has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

In the previous week, Fractyl Health had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 3 mentions for Fractyl Health and 1 mentions for ClearPoint Neuro. Fractyl Health's average media sentiment score of 1.90 beat ClearPoint Neuro's score of 0.36 indicating that Fractyl Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
ClearPoint Neuro
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fractyl Health has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -69.08%. ClearPoint Neuro's return on equity of -122.17% beat Fractyl Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Fractyl HealthN/A -2,896.77% -104.24%
ClearPoint Neuro -69.08%-122.17%-40.69%

Summary

Fractyl Health beats ClearPoint Neuro on 9 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

CapsoVision's return on equity of 0.00% beat Fractyl Health's return on equity.

Company Net Margins Return on Equity Return on Assets
CapsoVisionN/A N/A N/A
Fractyl Health N/A -2,896.77%-104.24%

CapsoVision has higher revenue and earnings than Fractyl Health. CapsoVision is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CapsoVision$13.55M25.97-$25.32M-$2.19N/A
Fractyl HealthN/AN/A-$140.95M-$1.84N/A

CapsoVision presently has a consensus target price of $8.50, indicating a potential upside of 20.40%. Fractyl Health has a consensus target price of $5.40, indicating a potential upside of 678.21%. Given Fractyl Health's higher possible upside, analysts clearly believe Fractyl Health is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Fractyl Health had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for Fractyl Health and 2 mentions for CapsoVision. Fractyl Health's average media sentiment score of 1.90 beat CapsoVision's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

CapsoVision and Fractyl Health tied by winning 6 of the 12 factors compared between the two stocks.

How does Fractyl Health compare to RxSight?

Fractyl Health (NASDAQ:GUTS) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Fractyl Health and Fractyl Health both had 3 articles in the media. Fractyl Health's average media sentiment score of 1.90 beat RxSight's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.8% of RxSight shares are owned by institutional investors. 26.1% of Fractyl Health shares are owned by company insiders. Comparatively, 9.6% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

RxSight has higher revenue and earnings than Fractyl Health. RxSight is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fractyl HealthN/AN/A-$140.95M-$1.84N/A
RxSight$134.48M2.24-$38.94M-$0.95N/A

Fractyl Health has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Fractyl Health presently has a consensus target price of $5.40, indicating a potential upside of 678.21%. RxSight has a consensus target price of $9.78, indicating a potential upside of 34.68%. Given Fractyl Health's stronger consensus rating and higher probable upside, research analysts plainly believe Fractyl Health is more favorable than RxSight.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
RxSight
3 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.93

Fractyl Health has a net margin of 0.00% compared to RxSight's net margin of -28.96%. RxSight's return on equity of -14.05% beat Fractyl Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Fractyl HealthN/A -2,896.77% -104.24%
RxSight -28.96%-14.05%-12.54%

Summary

Fractyl Health beats RxSight on 8 of the 14 factors compared between the two stocks.

How does Fractyl Health compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 26.1% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Fractyl Health has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -86.88%. TriSalus Life Sciences' return on equity of 0.00% beat Fractyl Health's return on equity.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-86.88% N/A -94.43%
Fractyl Health N/A -2,896.77%-104.24%

TriSalus Life Sciences currently has a consensus target price of $7.00, indicating a potential upside of 51.84%. Fractyl Health has a consensus target price of $5.40, indicating a potential upside of 678.21%. Given Fractyl Health's stronger consensus rating and higher probable upside, analysts plainly believe Fractyl Health is more favorable than TriSalus Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

TriSalus Life Sciences has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 3 articles in the media. Fractyl Health's average media sentiment score of 1.90 beat TriSalus Life Sciences' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

TriSalus Life Sciences has higher revenue and earnings than Fractyl Health. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M6.26-$39.23M-$1.83N/A
Fractyl HealthN/AN/A-$140.95M-$1.84N/A

Summary

Fractyl Health beats TriSalus Life Sciences on 8 of the 14 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for GUTS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GUTS vs. The Competition

Export
MetricFractyl HealthMED IndustryMedical SectorNASDAQ Exchange
Market Cap$110.09M$3.10B$6.24B$11.86B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio-0.3818.3729.0428.48
Price / SalesN/A272.31477.1060.43
Price / CashN/A50.4327.6236.52
Price / Book9.914.339.676.67
Net Income-$140.95M$72.19M$3.55B$332.64M
7 Day Performance5.73%2.03%1.70%2.01%
1 Month Performance52.20%6.42%5.62%9.19%
1 Year Performance-57.43%37.74%34.42%39.59%

Fractyl Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GUTS
Fractyl Health
3.6999 of 5 stars		$0.69
-4.6%		$5.40
+678.2%		N/A$110.09MN/AN/A102
DCTH
Delcath Systems
1.6232 of 5 stars		$10.84
flat		$22.50
+107.6%		N/A$373.49M$85.23M154.8660
CLPT
ClearPoint Neuro
1.7968 of 5 stars		$11.21
-4.8%		$14.50
+29.3%		N/A$353.23M$36.97MN/A110
CV
CapsoVision
1.5593 of 5 stars		$6.37
+4.9%		$8.50
+33.4%		N/A$302.52M$13.55MN/A90
RXST
RxSight
1.5643 of 5 stars		$7.29
+0.6%		$9.78
+34.1%		N/A$299.18M$134.48MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel